Target intelligence / Profile preview

Mucin-1 carrying Tn antigen (Tn-MUC1)

Target
Tn-MUC1
Molecular classification
Receptor, Other
01

Overview

Mucin-1 carrying Tn antigen (Tn-MUC1) is a tumor-associated glycoform of Mucin-1 (MUC1), a transmembrane glycoprotein normally expressed on the apical surface of simple glandular epithelial cells. During malignant transformation, cells undergo loss of apical-basal polarity and experience dysregulation of the O-glycosylation machinery, such as the inactivation of the molecular chaperone Cosmc (C1GALT1C1). This leads to the expression of aberrantly glycosylated, hypoglycosylated MUC1 carrying truncated O-glycans, most notably the Tn antigen (GalNAc-alpha-1-O-Ser/Thr). Unlike normal MUC1, which is heavily glycosylated and shielded from immune recognition, Tn-MUC1 exposes unique, highly cancer-specific neoepitopes that are virtually absent in healthy tissues, making it an exceptionally attractive target for selective cancer immunotherapy.

Tn-MUC1 is overexpressed in a wide range of epithelial cancers (adenocarcinomas), including breast, pancreatic, ovarian, non-small cell lung, and prostate cancers, as well as hematological malignancies like multiple myeloma and leukemia. Therapeutic strategies targeting Tn-MUC1 include chimeric antigen receptor (CAR) T-cell therapies (such as CART-TnMUC1-01), monoclonal antibodies (such as gatipotuzumab/PankoMab-GEX), antibody-drug conjugates (ADCs), and dendritic cell vaccines loaded with Tn-MUC1 glycopeptides. These agents exploit the tumor-specificity of the Tn-MUC1 glycoform to induce targeted tumor cell lysis via direct cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), or T-cell-mediated immune responses, while sparing normal tissues.

Other names
Tn-MUC1TnMUC1MUC1-TnTumor-associated Mucin-1Tumor-associated MUC1TA-MUC1tMUC1Mucin-1, cell surface associatedCD227EpisialinKrebs von den Lungen-6KL-6Cancer antigen 15-3CA 15-3
02

Mechanism of action

Chimeric antigen receptor T-cell (CAR-T) therapy targeting Tn-MUC1; Antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated by monoclonal antibodies; Antibody-drug conjugate (ADC) mediated cytotoxicity; Active immunotherapy via dendritic cell vaccination loaded with Tn-MUC1 glycopeptide

03

Biological functions

Signal transductionCell adhesionImmune responseCell survivalCell migrationOther
04

Disease associations

Cancer
05

Safety considerations

On-target, off-tumor toxicity (though Tn-MUC1 is highly tumor-specific, any low-level expression on normal tissues could cause toxicity)Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T therapyShedding of MUC1 (soluble MUC1 in circulation can act as a decoy, reducing drug efficacy)Tumor antigen heterogeneity (loss of Tn-MUC1 expression leading to tumor escape)
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Tn-MUC1 expression on tumor tissue (by immunohistochemistry)MUC1-Tn serum levelsPSA doubling time (PSADT) for prostate cancerC1GALT1C1 (Cosmc) deletion or mutation

Beyond the preview

Go deeper on Mucin-1 carrying Tn antigen (Tn-MUC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin-1 carrying Tn antigen (Tn-MUC1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call